 | |
| Clinical data | |
|---|---|
| Trade names | Sundralen, Symcorad, Symcor |
| ATC code | |
| Pharmacokinetic data | |
| Eliminationhalf-life | 2.3–5 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C8H10ClN3S |
| Molar mass | 215.70 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Tiamenidine (BAN,USAN,INN, also known asthiamenidine,Hoe 440) is animidazoline compound that shares many of the pharmacological properties ofclonidine. It is acentrally-actingα2 adrenergic receptoragonist (IC50 = 9.1 nM).[2] It also acts as anα1-adrenergic receptor agonist to a far lesser extent (IC50 = 4.85 μM).[2] In hypertensive volunteers, like clonidine, it significantly increased sinus node recovery time and loweredcardiac output.[3] It was marketed (as tiamenidine hydrochloride) bySanofi-Aventis[4] under the brand nameSundralen[5] for the management ofessential hypertension.[6]
Reaction of thiourea1 withmethyl iodide gives the corresponding S-methyl analogue (2), followed by heating withethylenediamine, completes the synthesis of tiamenidine (3).
